To ask the Secretary of State for Health and Social Care, with reference to the announcement by the US Food and Drug Administration in respect of the performance of Innova covid-19 tests, what plans he has for the authorisation of alternative covid-19 rapid lateral flow tests including those being produced in the UK; and if he will provide an update on an extension of the exceptional use authorisation from the Medicines and Healthcare products Regulatory Agency in respect of those tests in the context of continuing covid-19 restrictions.
Answered on
23 June 2021
I refer the hon. Member to the answer I gave to the hon. Member for Newton Abbot (Anne Marie Morris MP) on 21 June to Question 16120.
Answered by
Department of Health and Social Care